CliffBio
biologic

Ryplazim

plasminogen, human-tvmh

Loss of exclusivityJune 2033FDA regulatory exclusivity expiry
CompanyKedrion Biopharma, Inc. →View the full company profile on CliffBio

Drug detail

Brand nameRyplazim
Active ingredientplasminogen, human-tvmh
Strength68.8MG
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalJune 2021
Marketing statusRx

More from Kedrion Biopharma, Inc.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the FDA regulatory exclusivity expiry; estimates are projections, not legal advice.

Ryplazim patent cliff — loss of exclusivity June 2033 | CliffBio